HCHataichanok Chuljerm

Hataichanok Chuljerm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hataichanok Chuljerm has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 April 2026
      • Vol. 29  (2) , e70619
    Open Access

    Development and Validation of a Culturally Adapted Patient-Reported Experience Measure for Diabetes Care in Thailand: Mixed-Methods Study.

    by Soe Sandi Tint, Nida Buawangpong, Wichuda Jiraporncharoen, Myo Zin Oo, Nutchar Wiwatkunupakarn, Kittipan Rerkasem, Kanokwan Kulprachakarn, Hataichanok Chuljerm, Timothy E O'BRien, Rohini Mathur, et al.

    Patient-centred care is essential for managing Type 2 diabetes, as it relies on understanding patients' experiences and perspectives. However, in Thailand, no culturally adapted patient-reported experience measure (PREM) exists to capture these insights and support quality improvement in diabetes care. To develop and validate a culturally adapted PREM for Thai people with Type 2 diabetes receiving primary care. This mixed-methods study was conducted at Saraphi Hospital, Chiang Mai, from July to December 2024. Stage 1 involved drafting the initial PREM based on a prior scoping review. In Stage 2, content validity was assessed by experts, and face validity was evaluated through patient interviews. Stage 3 involved a quantitative survey of patients to assess construct validity and reliability using exploratory and confirmatory factor analyses. The initial PREM included 37 items across four domains, developed based on findings from the scoping review. After expert and patient feedback, the tool was refined. Exploratory and confirmatory factor analyses confirmed the tool's structure, resulting in a final version with 16 items across four domains: care planning, patient education, professionalism and quality of service. This final PREM structure explained 60.1% of overall variance, and demonstrated good internal consistency (Cronbach's alpha of 0.84), supporting its utility for capturing patient experiences in the Thai healthcare setting. This study developed the first culturally adapted PREM for Thai people living with diabetes. Although further implementation is needed, this current validated tool can support patient-centred care in Thailand and other low- and middle-income settings in Southeast Asia. The development of this instrument actively involved patients throughout key stages. During content validation, individuals living with diabetes participated in an expert panel and provided feedback on item clarity, relevance and comprehensiveness. Their suggestions directly influenced revisions to the questionnaire. For face validity, a pilot test was conducted with patients in a primary care setting, gathering their insights on wording, usability and cultural appropriateness. Their contributions ensured the tool was clear, acceptable and contextually relevant to Thai people living with diabetes.


  • Open Access

    Development and Validation of a Culturally Adapted Patient‐Reported Experience Measure for Diabetes Care in Thailand: Mixed‐Methods Study

    by Soe Sandi Tint, Nida Buawangpong, Wichuda Jiraporncharoen, Myo Zin Oo, Nutchar Wiwatkunupakarn, Kittipan Rerkasem, Kanokwan Kulprachakarn, Hataichanok Chuljerm, Timothy E. O'BRien, Rohini Mathur, et al.

    Background: Patient‐centred care is essential for managing Type 2 diabetes, as it relies on understanding patients’ experiences and perspectives. However, in Thailand, no culturally adapted patient‐reported experience measure (PREM) exists to capture these insights and support quality improvement in diabetes care. Objective: To develop and validate a culturally adapted PREM for Thai people with Type 2 diabetes receiving primary care. Methods: This mixed‐methods study was conducted at Saraphi Hospital, Chiang Mai, from July to December 2024. Stage 1 involved drafting the initial PREM based on a prior scoping review. In Stage 2, content validity was assessed by experts, and face validity was evaluated through patient interviews. Stage 3 involved a quantitative survey of patients to assess construct validity and reliability using exploratory and confirmatory factor analyses. Results: The initial PREM included 37 items across four domains, developed based on findings from the scoping review. After expert and patient feedback, the tool was refined. Exploratory and confirmatory factor analyses confirmed the tool's structure, resulting in a final version with 16 items across four domains: care planning, patient education, professionalism and quality of service. This final PREM structure explained 60.1% of overall variance, and demonstrated good internal consistency (Cronbach's alpha of 0.84), supporting its utility for capturing patient experiences in the Thai healthcare setting. Conclusion: This study developed the first culturally adapted PREM for Thai people living with diabetes. Although further implementation is needed, this current validated tool can support patient‐centred care in Thailand and other low‐ and middle‐income settings in Southeast Asia. Patient or Public Contribution: The development of this instrument actively involved patients throughout key stages. During content validation, individuals living with diabetes participated in an expert panel and provided feedback on item clarity, relevance and comprehensiveness. Their suggestions directly influenced revisions to the questionnaire. For face validity, a pilot test was conducted with patients in a primary care setting, gathering their insights on wording, usability and cultural appropriateness. Their contributions ensured the tool was clear, acceptable and contextually relevant to Thai people living with diabetes.


  • Open Access

    Deferiprone−Resveratrol Hybrid, an Iron‐Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei‐Infected Mice

    by Hataichanok Chuljerm, Supawadee Maneekesorn, Chuchard Punsawad, Voravuth Somsak, Yongmin Ma, Jetsada Ruangsuriya, Somdet Srichairatanakool, Pimpisid Koonyosying

    Free heme in plasma acts as a prooxidant; thus, it is bound to hemopexin and eliminated by the liver. High iron content in the liver can support Plasmodium growth and cause oxidative liver injury. Inversely, the withholding of excessive iron can inhibit this growth and protect the liver against malaria infection. This study examined the effects of a deferiprone‐resveratrol (DFP‐RVT) hybrid on malaria parasites and its relevant hepatoprotective properties. Mice were infected with P. berghei, gavage DFP‐RVT, deferiprone (DFP), and pyrimethamine (PYR) for 8 consecutive days. Blood and liver parameters were then evaluated. The presence of blood‐stage parasites was determined using the microscopic Giemsa staining method. Subsequently, plasma liver enzymes, heme, and concentrations of thiobarbituric acid‐reactive substances (TBARS) were determined. The liver tissue was examined pathologically and heme and TBARS concentrations were then quantified. The results indicate that the suppression potency against P. berghei growth occurred as follows: PYR > DFP‐RVT hybrid > DFP. Importantly, DFP‐RVT significantly improved RBC size, restored alanine aminotransferase and alkaline activities, and increased heme and TBARS concentrations. The compound also reduced the liver weight index, heme, and TBARS concentrations significantly when compared to mice that were untreated. Our findings support the contention that the hepatoprotective effect of DFP‐RVT is associated with parasite burden, iron depletion, and lipid peroxidation in the host.


  • Open Access

    Anti-Malarial and Anti-Lipid Peroxidation Activities of Deferiprone-Resveratrol Hybrid in Plasmodium berghei-Infected Mice

    by Hataichanok Chuljerm, Supawadee Maneekesorn, Voravuth Somsak, Yongmin Ma, Somdet Srichairatanakool, Pimpisid Koonyosying

    Iron is essential for all organisms including fast-dividing malarial parasites. Inversely, iron chelators can inhibit parasite growth through the inhibition of DNA synthesis and can ameliorate oxidative cell damage. Deferiprone (DFP)-resveratrol (RVT) hybrid (DFP-RVT) is a lipophilic anti-oxidative, iron-chelating agent that has displayed potent neuroprotective and anti-plasmodium activities in vitro. The goal of this work was to investigate the inhibitory effects of DFP-RVT on parasite growth and oxidative stress levels during malaria infections. Mice were intraperitoneally infected with P. berghei and orally administered with DFP, DFP-RVT and pyrimethamine for 4 d. The percentage of parasitemia was determined using Giemsa’s staining/microscopic examination. Amounts of the lipid-peroxidation product, thiobarbituric acid-reactive substance (TBARS), were determined in both plasma and liver tissue. In our findings, DFP-RVT exhibited a greater potent inhibitory effect and revealed an improvement in anemia and liver damage in infected mice than DFP. To this point, the anti-malarial activity was found to be associated with anti-RBC hemolysis and the liver weight index. In addition, plasma and liver TBARS levels in the DFP-RVT-treated mice were lower than those in DFP-treated mice. Thus, DFP-RVT could exert anti-plasmodium, anti-hemolysis and anti-lipid peroxidation activities to a better degree than DFP in P. berghei-infected mice.